Gabri Labs, a pharmaceutical technologies company headquartered in the US, has announced the development of a 10,000 sq. ft. facility to locally produce medical devices.

The global firm has signed on with Dubai Science Park to construct a medical devices facility at an AED 18 million (approx. Rs 37 crore) investment, reinforcing Dubai’s attractiveness as a global hub for healthcare and pharmaceutical manufacturing.

Gabri Lab’s new facility will enable the pharmaceutical brand to produce an initial volume of 12 million units per year with further expansions planned by 2023. The medical devices will be distributed to markets across the Middle East and North Africa (MENA) region.

Gabri Labs has earned its reputation in the therapeutic ENT and dermatology spheres for developing high-quality, innovative over-the-counter products and medical devices. The new facility in Dubai will support the production of multiple lines and a diverse product portfolio, which includes ENT brand, OTOMAR, and dermatological solutions line, Curadem.